Since NF-κB signaling has been implicated in HCC progression (100) and sorafenib resistance (101), its activation may be a potent mechanism leading to SHP2 upregulation in both parental and sorafenib-resistant HCC cells. The gene discussed is PTPN11; the disease is hepatocellular carcinoma.